Profacgen specializes in advanced protein services and technologies, focusing on custom protein production, analysis, and drug development. Their offerings include a range of services such as recombinant protein expression, protein engineering, and the development of stable cell lines for protein expression. They utilize cutting-edge techniques like Surface Plasmon Resonance (SPR) for protein interaction analysis and provide comprehensive bioinformatics support for data management and analysis. Profacgen is also involved in the production of nanozymes, which are nanomaterials with enzymatic properties that can catalyze reactions under mild conditions, offering advantages over natural enzymes in terms of stability and efficiency.

Additionally, Profacgen is at the forefront of innovative drug development technologies, particularly in the area of targeted protein degradation using PROteolysis TArgeting Chimeras (PROTACs). This technology leverages the ubiquitin-proteasome system to selectively degrade target proteins associated with diseases, including various cancers. Their services extend to the expression and purification of E3 ligases and target proteins, which are crucial for the design and optimization of PROTACs. By integrating protein ubiquitination studies and novel E3 ligase discovery, Profacgen aims to enhance therapeutic strategies and precision medicine approaches in drug development.

United States

Profacgen offers a full range of biopharmaceutical development and bio-manufacturing services that cover strategic consultancy,process development, cGMP manufacturing, and analytical development.

Profacgen

Company Details